awmsg logo



saxagliptin (Onglyza®)


Reference No. 1005

Publication date:
12/01/2012


Appraisal information

saxagliptin (Onglyza®) film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: 03/11/2011
AWMSG meeting date: 07/12/2011
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2011
Ministerial ratification: 09/01/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales as an add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control. AWMSG is of the opinion that saxagliptin (Onglyza®) may be suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download